A citation-based method for searching scientific literature

Dinesh Khanna, Christopher P Denton, Celia J F Lin, Jacob M van Laar, Tracy M Frech, Marina E Anderson, Murray Baron, Lorinda Chung, Gerhard Fierlbeck, Santhanam Lakshminarayanan, Yannick Allanore, Janet E Pope, Gabriela Riemekasten, Virginia Steen, Ulf Müller-Ladner, Helen Spotswood, Laura Burke, Jeffrey Siegel, Angelika Jahreis, Daniel E Furst. Ann Rheum Dis 2018
Times Cited: 122







List of co-cited articles
1050 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.
Dinesh Khanna, Christopher P Denton, Angelika Jahreis, Jacob M van Laar, Tracy M Frech, Marina E Anderson, Murray Baron, Lorinda Chung, Gerhard Fierlbeck, Santhanam Lakshminarayanan,[...]. Lancet 2016
281
41

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler, Kristin B Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D Mayes, Ganesh Raghu, Wiebke Sauter, Mannaig Girard, Margarida Alves,[...]. N Engl J Med 2019
368
40

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Donald P Tashkin, Michael D Roth, Philip J Clements, Daniel E Furst, Dinesh Khanna, Eric C Kleerup, Jonathan Goldin, Edgar Arriola, Elizabeth R Volkmann, Suzanne Kafaja,[...]. Lancet Respir Med 2016
373
37

Cyclophosphamide versus placebo in scleroderma lung disease.
Donald P Tashkin, Robert Elashoff, Philip J Clements, Jonathan Goldin, Michael D Roth, Daniel E Furst, Edgar Arriola, Richard Silver, Charlie Strange, Marcy Bolster,[...]. N Engl J Med 2006
908
32

Update of EULAR recommendations for the treatment of systemic sclerosis.
Otylia Kowal-Bielecka, Jaap Fransen, Jerome Avouac, Mike Becker, Agnieszka Kulak, Yannick Allanore, Oliver Distler, Philip Clements, Maurizio Cutolo, Laszlo Czirjak,[...]. Ann Rheum Dis 2017
358
30

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
Dinesh Khanna, Carlo Albera, Aryeh Fischer, Nader Khalidi, Ganesh Raghu, Lorinda Chung, Dan Chen, Elena Schiopu, Margit Tagliaferri, James R Seibold,[...]. J Rheumatol 2016
121
27

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.
Keith M Sullivan, Ellen A Goldmuntz, Lynette Keyes-Elstein, Peter A McSweeney, Ashley Pinckney, Beverly Welch, Maureen D Mayes, Richard A Nash, Leslie J Crofford, Barry Eggleston,[...]. N Engl J Med 2018
192
25

Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial.
Jacob M van Laar, Dominique Farge, Jacob K Sont, Kamran Naraghi, Zora Marjanovic, Jérôme Larghero, Annemie J Schuerwegh, Erik W A Marijt, Madelon C Vonk, Anton V Schattenberg,[...]. JAMA 2014
339
25

Systemic sclerosis.
Christopher P Denton, Dinesh Khanna. Lancet 2017
546
25

Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Suzana Jordan, Jörg H W Distler, Britta Maurer, Dörte Huscher, Jacob M van Laar, Yannick Allanore, Oliver Distler. Ann Rheum Dis 2015
217
22

Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
Richard K Burt, Sanjiv J Shah, Karin Dill, Thomas Grant, Mihai Gheorghiade, James Schroeder, Robert Craig, Ikuo Hirano, Karin Marshall, Eric Ruderman,[...]. Lancet 2011
272
20

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
Rachel K Hoyles, Ross W Ellis, Jessica Wellsbury, Belinda Lees, Pauline Newlands, Nicole S L Goh, Christopher Roberts, Sujal Desai, Ariane L Herrick, Neil J McHugh,[...]. Arthritis Rheum 2006
406
19

Interstitial lung disease in systemic sclerosis: a simple staging system.
Nicole S L Goh, Sujal R Desai, Srihari Veeraraghavan, David M Hansell, Susan J Copley, Toby M Maher, Tamera J Corte, Clare R Sander, Jonathan Ratoff, Anand Devaraj,[...]. Am J Respir Crit Care Med 2008
570
17

Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.
Muriel Elhai, Marouane Boubaya, Oliver Distler, Vanessa Smith, Marco Matucci-Cerinic, Juan José Alegre Sancho, Marie-Elise Truchetet, Yolanda Braun-Moscovici, Florenzo Iannone, Pavel I Novikov,[...]. Ann Rheum Dis 2019
65
26

Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial.
Geetabali Sircar, Rudra Prosad Goswami, Dipankar Sircar, Alakendu Ghosh, Parasar Ghosh. Rheumatology (Oxford) 2018
70
24

A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Dimitrios Daoussis, Konstantinos Melissaropoulos, Georgios Sakellaropoulos, Ioannis Antonopoulos, Theodora E Markatseli, Theodora Simopoulou, Panagiotis Georgiou, Andrew P Andonopoulos, Alexandros A Drosos, Lazaros Sakkas,[...]. Semin Arthritis Rheum 2017
90
17

Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.
Anthony J Tyndall, Bettina Bannert, Madelon Vonk, Paolo Airò, Franco Cozzi, Patricia E Carreira, Dominique Farge Bancel, Yannick Allanore, Ulf Müller-Ladner, Oliver Distler,[...]. Ann Rheum Dis 2010
606
16

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.
Christopher P Denton, Voon H Ong, Shiwen Xu, Haiyin Chen-Harris, Zora Modrusan, Robert Lafyatis, Dinesh Khanna, Angelika Jahreis, Jeffrey Siegel, Thierry Sornasse. Ann Rheum Dis 2018
54
29

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Dinesh Khanna, Celia J F Lin, Daniel E Furst, Jonathan Goldin, Grace Kim, Masataka Kuwana, Yannick Allanore, Marco Matucci-Cerinic, Oliver Distler, Yoshihito Shima,[...]. Lancet Respir Med 2020
56
28

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease.
Donald P Tashkin, Robert Elashoff, Philip J Clements, Michael D Roth, Daniel E Furst, Richard M Silver, Jonathan Goldin, Edgar Arriola, Charlie Strange, Marcy B Bolster,[...]. Am J Respir Crit Care Med 2007
262
15

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser,[...]. N Engl J Med 2019
383
15

Short-Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis.
Nicole S Goh, Rachel K Hoyles, Christopher P Denton, David M Hansell, Elisabetta A Renzoni, Toby M Maher, Andrew G Nicholson, Athol U Wells. Arthritis Rheumatol 2017
121
14

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
14

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.
Frank van den Hoogen, Dinesh Khanna, Jaap Fransen, Sindhu R Johnson, Murray Baron, Alan Tyndall, Marco Matucci-Cerinic, Raymond P Naden, Thomas A Medsger, Patricia E Carreira,[...]. Arthritis Rheum 2013
14

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.
Dimitrios Daoussis, Stamatis-Nick C Liossis, Athanassios C Tsamandas, Christina Kalogeropoulou, Alexandra Kazantzi, Chaido Sirinian, Maria Karampetsou, Georgios Yiannopoulos, Andrew P Andonopoulos. Rheumatology (Oxford) 2010
240
13

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
13

Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis.
Jingang Huang, Christiane Maier, Yun Zhang, Alina Soare, Clara Dees, Christian Beyer, Ulrike Harre, Chih-Wei Chen, Oliver Distler, Georg Schett,[...]. Ann Rheum Dis 2017
76
17

Severe restrictive lung disease in systemic sclerosis.
V D Steen, C Conte, G R Owens, T A Medsger. Arthritis Rheum 1994
354
12

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial.
Dinesh Khanna, Cathie Spino, Sindhu Johnson, Lorinda Chung, Michael L Whitfield, Christopher P Denton, Veronica Berrocal, Jennifer Franks, Bhavan Mehta, Jerry Molitor,[...]. Arthritis Rheumatol 2020
66
18

Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study.
Muriel Elhai, Marine Meunier, Marco Matucci-Cerinic, Britta Maurer, Gabriela Riemekasten, Tifenn Leturcq, Raffaele Pellerito, Carlos Alberto Von Mühlen, Alessandra Vacca, Paolo Airo,[...]. Ann Rheum Dis 2013
104
11

Treatment Algorithms for Systemic Sclerosis According to Experts.
Andreu Fernández-Codina, Kyle M Walker, Janet E Pope. Arthritis Rheumatol 2018
74
14

Changes in causes of death in systemic sclerosis, 1972-2002.
Virginia D Steen, Thomas A Medsger. Ann Rheum Dis 2007
915
11

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative.
Frank van den Hoogen, Dinesh Khanna, Jaap Fransen, Sindhu R Johnson, Murray Baron, Alan Tyndall, Marco Matucci-Cerinic, Raymond P Naden, Thomas A Medsger, Patricia E Carreira,[...]. Ann Rheum Dis 2013
871
11

Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.
Angelo De Lauretis, Piersante Sestini, Panagiotis Pantelidis, Rachel Hoyles, David M Hansell, Nicole S L Goh, Christopher J Zappala, Dina Visca, Toby M Maher, Christopher P Denton,[...]. J Rheumatol 2013
124
10

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
William D Travis, Ulrich Costabel, David M Hansell, Talmadge E King, David A Lynch, Andrew G Nicholson, Christopher J Ryerson, Jay H Ryu, Moisés Selman, Athol U Wells,[...]. Am J Respir Crit Care Med 2013
9

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension.
Sean Gaine, Kelly Chin, Gerry Coghlan, Richard Channick, Lilla Di Scala, Nazzareno Galiè, Hossein-Ardeschir Ghofrani, Irene M Lang, Vallerie McLaughlin, Ralph Preiss,[...]. Eur Respir J 2017
42
21

Belimumab for the Treatment of Early Diffuse Systemic Sclerosis: Results of a Randomized, Double-Blind, Placebo-Controlled, Pilot Trial.
Jessica K Gordon, Viktor Martyanov, Jennifer M Franks, Elana J Bernstein, Jackie Szymonifka, Cynthia Magro, Horatio F Wildman, Tammara A Wood, Michael L Whitfield, Robert F Spiera. Arthritis Rheumatol 2018
41
21

Scleroderma.
Armando Gabrielli, Enrico V Avvedimento, Thomas Krieg. N Engl J Med 2009
938
9

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.
Lisa M Rice, Cristina M Padilla, Sarah R McLaughlin, Allison Mathes, Jessica Ziemek, Salma Goummih, Sashidhar Nakerakanti, Michael York, Giuseppina Farina, Michael L Whitfield,[...]. J Clin Invest 2015
176
9

Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
Elizabeth R Volkmann, Donald P Tashkin, Myung Sim, Ning Li, Ellen Goldmuntz, Lynette Keyes-Elstein, Ashley Pinckney, Daniel E Furst, Philip J Clements, Dinesh Khanna,[...]. Ann Rheum Dis 2019
60
15

Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model.
Wanlong Wu, Suzana Jordan, Mike Oliver Becker, Rucsandra Dobrota, Britta Maurer, Håvard Fretheim, Shuang Ye, Elise Siegert, Yannick Allanore, Anna-Maria Hoffmann-Vold,[...]. Ann Rheum Dis 2018
46
19

Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis.
Jingang Huang, Christian Beyer, Katrin Palumbo-Zerr, Yun Zhang, Andreas Ramming, Alfiya Distler, Kolja Gelse, Oliver Distler, Georg Schett, Lutz Wollin,[...]. Ann Rheum Dis 2016
102
9

JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis.
Clara Dees, Michal Tomcik, Katrin Palumbo-Zerr, Alfiya Distler, Christian Beyer, Veronika Lang, Angelika Horn, Pawel Zerr, Jochen Zwerina, Kolja Gelse,[...]. Arthritis Rheum 2012
76
10

The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.
Yoshihito Shima, Yusuke Kuwahara, Hiroyuki Murota, Shun Kitaba, Mari Kawai, Toru Hirano, Junsuke Arimitsu, Masashi Narazaki, Keisuke Hagihara, Atsushi Ogata,[...]. Rheumatology (Oxford) 2010
130
8

Scleroderma lung disease.
Joshua J Solomon, Amy L Olson, Aryeh Fischer, Todd Bull, Kevin K Brown, Ganesh Raghu. Eur Respir Rev 2013
119
8

Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials.
Dinesh Khanna, Vivek Nagaraja, Chi-Hong Tseng, Fereidoun Abtin, Robert Suh, Grace Kim, Athol Wells, Daniel E Furst, Philip J Clements, Michael D Roth,[...]. Arthritis Res Ther 2015
49
16

Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
Suzanne Kafaja, Philip J Clements, Holly Wilhalme, Chi-Hong Tseng, Daniel E Furst, Grace Hyun Kim, Jonathan Goldin, Elizabeth R Volkmann, Michael D Roth, Donald P Tashkin,[...]. Am J Respir Crit Care Med 2018
38
21

Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review.
Tiffany A Winstone, Deborah Assayag, Pearce G Wilcox, James V Dunne, Cameron J Hague, Jonathon Leipsic, Harold R Collard, Christopher J Ryerson. Chest 2014
115
8

Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.
Julie Morisset, Eric Vittinghoff, Brett M Elicker, Xiaowen Hu, Stephanie Le, Jay H Ryu, Kirk D Jones, Anna Haemel, Jeffrey A Golden, Francesco Boin,[...]. Chest 2017
33
24

Systemic sclerosis.
Yannick Allanore, Robert Simms, Oliver Distler, Maria Trojanowska, Janet Pope, Christopher P Denton, John Varga. Nat Rev Dis Primers 2015
275
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.